MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme

Brain Research

Volumn 1286, Issue , 2009, Pages 13-18

  Li, Yiming ^a   Li, Weiqing ^a   Yang, Yongji ^b   Lu, Yicheng ^a   He, Cheng ^b   Hu, Guohan ^a   Liu, Huimin ^a   Chen, Juxiang ^a   He, Jin ^a   Yu, Hongyu ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Drug resistance; Glioblastoma; LRRFIP1; miR 21; VM 26

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; GENE PRODUCT; LEUCINE RICH REPEAT IN FLII INTERACTING PROTEIN 1; MICRORNA; MICRORNA 21; TENIPOSIDE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWNSTREAM PROCESSING; DRUG CYTOTOXICITY; DRUG POTENTIATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE REPRESSION; GENE TARGETING; GLIOBLASTOMA; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MICRORNAS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA-BINDING PROTEINS; TENIPOSIDE; TRANSFECTION;

EID: 67849103555     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.06.053     Document Type: Article

References (29)

1. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 (2004) 281-297
2. Blower P.E., Verducci J.S., Lin S., Zhou J., Chung J.H., Dai Z., Liu C.G., Reinhold W., Lorenzi P.L., Kaldjian E.P., Croce C.M., Weinstein J.N., and Sadee W. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol. Cancer Ther. 6 (2007) 1483-1491
3. Brandes A.A., Rigon A., Zampieri P., Ermani M., Carollo C., Altavilla G., Turazzi S., Chierichetti F., and Florentino M.V. Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study. Cancer 82 (1998) 355-361
4. Chan J.A., Krichevsky A.M., and Kosik K.S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 65 (2005) 6029-6033
5. Chen C., Ridzon D.A., Broomer A.J., Zhou Z., Lee D.H., Nguyen J.T., Barbisin M., Xu N.L., Mahuvakar V.R., Andersen M.R., Lao K.Q., Livak K.J., and Guegler K.J. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33 (2005) e179
6. Corsten M.F., Miranda R., Kasmieh R., Krichevsky A.M., Weissleder R., and Shah K. MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res. 67 (2007) 8994-9000
7. Fine H.A., Dear K.B., Loeffler J.S., Black P.M., and Canellos G.P. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71 (1993) 2585-2597
8. Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist. Updat. 10 (2007) 59-67
9. Hinz M., Loser P., Mathas S., Krappmann D., Dorken B., and Scheidereit C. Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood 97 (2001) 2798-2807
10. Huang S., DeGuzman A., Bucana C.D., and Fidler I.J. Nuclear factor-kappaB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin. Cancer Res. 6 (2000) 2573-2581
11. Iorio M.V., Ferracin M., Liu C.G., Veronese A., Spizzo R., Sabbioni S., Magri E., Pedriali M., Fabbri M., Campiglio M., Menard S., Palazzo J.P., Rosenberg A., Musiani P., Volinia S., Nenci I., Calin G.A., Querzoli P., Negrini M., and Croce C.M. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65 (2005) 7065-7070
12. Karin M., Yamamoto Y., and Wang Q.M. The IKK NF-kappa B system: a treasure trove for drug development. Nat. Rev. Drug Discov. 3 (2004) 17-26
13. La Ferla-Bruhl K., Westhoff M.A., Karl S., Kasperczyk H., Zwacka R.M., Debatin K.M., and Fulda S. NF-kappaB-independent sensitization of glioblastoma cells for TRAIL-induced apoptosis by proteasome inhibition. Oncogene 26 (2007) 571-582
14. Lee S.Y., and Choi Y. TRAF-interacting protein (TRIP): a novel component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits TRAF2-mediated NF-kappaB activation. J. Exp. Med. 185 (1997) 1275-1285
15. Mane J.M., Fernandez R., Munoz A., Rubio I., Ferreiro J., Lopez-Argumedo G., Barcelo R., and Lopez-Vivanco G. Preradiation chemotherapy with VM-26 and CCNU in patients with glioblastoma multiforme. Tumori 90 (2004) 562-566
16. Mason W.P., and Cairncross J.G. Drug insight: temozolomide as a treatment for malignant glioma-impact of a recent trial. Nat. Clin. Pract. Neurol. 1 (2005) 88-95
17. Mishra P.J., Humeniuk R., Longo-Sorbello G.S., Banerjee D., and Bertino J.R. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 13513-13518
18. Nakanishi C., and Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer 5 (2005) 297-309
19. Papagiannakopoulos T., Shapiro A., and Kosik K.S. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res. 68 (2008) 8164-8172
20. Roldo C., Missiaglia E., Hagan J.P., Falconi M., Capelli P., Bersani S., Calin G.A., Volinia S., Liu C.G., Scarpa A., and Croce C.M. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J. Clin. Oncol. 24 (2006) 4677-4684
21. Si M.L., Zhu S., Wu H., Lu Z., Wu F., and Mo Y.Y. miR-21-mediated tumor growth. Oncogene 26 (2007) 2799-2803
22. Sklansky B.D., Mann-Kaplan R.S., Reynolds Jr. A.F., Rosenblum M.L., and Walker M.D. Proceedings: 4′-demethyl-epipodophyllotoxin-beta-d-thenylidene-glucoside (PTG) in the treatment of malignant intracranial neoplasms. Cancer 33 (1974) 460-467
23. Stewart L.A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359 (2002) 1011-1018
24. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., and Mirimanoff R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352 (2005) 987-996
25. Wang C.Y., Cusack Jr. J.C., Liu R., and Baldwin Jr. A.S. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat. Med. 5 (1999) 412-417
26. Wang W., Abbruzzese J.L., Evans D.B., Larry L., Cleary K.R., and Chiao P.J. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin. Cancer Res. 5 (1999) 119-127
27. Weller M., Muller B., Koch R., Bamberg M., and Krauseneck P. Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J. Clin. Oncol. 21 (2003) 3276-3284
28. Wen P.Y., and Kesari S. Malignant gliomas in adults. N. Engl. J. Med. 359 (2008) 492-507
29. Zhu S., Si M.L., Wu H., and Mo Y.Y. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J. Biol. Chem. 282 (2007) 14328-14336